ATE420355T1 - Diagnostik für übertragbare spongiforme enzephalopathie - Google Patents

Diagnostik für übertragbare spongiforme enzephalopathie

Info

Publication number
ATE420355T1
ATE420355T1 AT01127425T AT01127425T ATE420355T1 AT E420355 T1 ATE420355 T1 AT E420355T1 AT 01127425 T AT01127425 T AT 01127425T AT 01127425 T AT01127425 T AT 01127425T AT E420355 T1 ATE420355 T1 AT E420355T1
Authority
AT
Austria
Prior art keywords
cells
cell
spongiform encephalopathy
diagnostics
infective
Prior art date
Application number
AT01127425T
Other languages
English (en)
Inventor
Adriano Aguzzi
Michael A Klein
Alex Raeber
Charles Weissmann
Rolf Zinkernagel
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of ATE420355T1 publication Critical patent/ATE420355T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
AT01127425T 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme enzephalopathie ATE420355T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01127425A EP1215497B1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme Enzephalopathie
EP97122186A EP0931551B1 (de) 1997-12-16 1997-12-16 Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte

Publications (1)

Publication Number Publication Date
ATE420355T1 true ATE420355T1 (de) 2009-01-15

Family

ID=8227810

Family Applications (3)

Application Number Title Priority Date Filing Date
AT97122186T ATE358497T1 (de) 1997-12-16 1997-12-16 Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte
AT01127424T ATE427120T1 (de) 1997-12-16 1997-12-16 T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten
AT01127425T ATE420355T1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme enzephalopathie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
AT97122186T ATE358497T1 (de) 1997-12-16 1997-12-16 Verfahren zur herstellung von mittel zur therapie der übertragbaren spongiformen enzephalopathie und nicht-infektiösen blut- und gewebeprodukten sowie die hergestellten produkte
AT01127424T ATE427120T1 (de) 1997-12-16 1997-12-16 T-zellen therapeutika fur ubertragbare spongiforme encephalopathie und methode zur herstellung von nicht infektiísen blut-produkten und von geweben abgeleiteten produkten

Country Status (9)

Country Link
US (1) US20080063600A1 (de)
EP (4) EP0931551B1 (de)
JP (1) JP2002508335A (de)
AT (3) ATE358497T1 (de)
AU (1) AU2613199A (de)
CA (1) CA2348660A1 (de)
DE (3) DE69739210D1 (de)
ES (3) ES2320314T3 (de)
WO (1) WO1999030738A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2291720A1 (en) * 1997-05-30 1998-12-03 Ernst-Ludwig Winnacker Pharmaceutical compositions comprising a soluble laminin receptor precursor of a compound which blocks the interaction of the laminin receptor precursor and prpsc or prpc
CA2372603C (en) 1999-05-07 2015-11-17 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
GB0110172D0 (en) * 2001-04-25 2001-06-20 Pa Consulting Services Improved analytical test approach for blood
EP1921451A3 (de) 2001-05-22 2008-05-28 Cygene, Inc. Komplement-vermittelte Assays für In-vivo- und In-vitro-Verfahren
NZ569448A (en) * 2005-12-08 2011-12-22 Univ South Dakota Method of in vitro propagation and detection of infectious prion using follicular dendritic cell cultures co-cultured with B cells
US7601506B2 (en) 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
WO2009000406A1 (en) * 2007-06-22 2008-12-31 Bayer Healthcare Ag Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
WO2012048298A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
CN106715676A (zh) 2014-09-26 2017-05-24 泰尔茂比司特公司 按计划供养
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3601521A2 (de) 2017-03-31 2020-02-05 Terumo BCT, Inc. Zellexpansion
ES2954311T3 (es) 2017-04-01 2023-11-21 Avm Biotechnology Llc Reemplazo de un preacondicionamiento citotóxico antes de una inmunoterapia celular

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273882A (en) 1985-06-13 1993-12-28 Amgen Method and kit for performing nucleic acid hybridization assays
US5055290A (en) 1985-12-18 1991-10-08 Boehringer Mannehim Gmbh Ciamexone as a selective immunosuppressant
ATE130197T1 (de) * 1988-06-14 1995-12-15 Cell Med Inc Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
US5369119A (en) 1988-07-28 1994-11-29 Boehringer Mannheim Gmbh Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
ATE263374T1 (de) * 1995-09-14 2004-04-15 Univ California Für natives prp-sc spezifische antikörper
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
DE69739344D1 (de) 2009-05-14
AU2613199A (en) 1999-07-05
WO1999030738A3 (en) 1999-10-21
ES2285720T3 (es) 2007-11-16
ATE358497T1 (de) 2007-04-15
EP1215497A1 (de) 2002-06-19
DE69737557T2 (de) 2007-12-20
ES2324334T3 (es) 2009-08-05
CA2348660A1 (en) 1999-06-24
EP0931551B1 (de) 2007-04-04
JP2002508335A (ja) 2002-03-19
EP1214943B1 (de) 2009-04-01
DE69739210D1 (de) 2009-02-26
EP1044020A2 (de) 2000-10-18
DE69737557D1 (de) 2007-05-16
WO1999030738A2 (en) 1999-06-24
EP0931551A1 (de) 1999-07-28
EP1214943A1 (de) 2002-06-19
ATE427120T1 (de) 2009-04-15
US20080063600A1 (en) 2008-03-13
EP1215497B1 (de) 2009-01-07
ES2320314T3 (es) 2009-05-21

Similar Documents

Publication Publication Date Title
ATE420355T1 (de) Diagnostik für übertragbare spongiforme enzephalopathie
Caul Small round structured viruses: airborne transmission and hospital control.
CY1107550T1 (el) Συνδυαστικα εμβολια μηνιγγιτιδας b/c
BR9712289A (pt) Composições e métodos para o tratamento de infecções virais
ATE418562T1 (de) Ctl epitope des epstein-barr virus
HUP0202502A2 (hu) Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására
HUP0302636A2 (hu) Hasított burkolt víruskészítmény
DE820303T1 (de) p277 PEPTIDANALOGE, PHARMAZEUTISCHE ZUSAMMENSTELLUNG DAVON ZUR BEHANDLUNG UND DIAGNOSE VON DIABETES
ES495939A0 (es) Un procedimiento de preparacion de una vacuna de virus vivosde la peritonitis infecciosa de los felinos
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DK0484438T3 (da) Biologisk præparat og dets anvendelse
WO2000041463A3 (en) Combination of hepatitis b vaccine with antiviral agents
HUP9801572A2 (hu) Chlamydia-vakcinák
DE10075036I2 (de) Impfstoff und Diagnostikum f}r den Schweine-Cholera-Virus.
NO910869D0 (no) Fremgangsmaate for desinfeksjon av medisinsk avstoepningsmasse.
EE03514B1 (et) Ühendite kombinatsioon HIV infektsiooni või AIDS-i raviks, selle kasutamine ja farmatseutiline kompositsioon
DK0821593T3 (da) Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein
DK0516725T3 (da) Ny anvendelse af Linomide
FR2712493B1 (fr) Utilisation de photosensibilisateurs dérivés du noyau phorbine pour la décontamination du sang infecté par des parasites et/ou des virus.
ATE80553T1 (de) Behandlung von viraler infektion.
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
HUP9901488A2 (hu) Kontrasztanyagok
Kissinger Geneva conference points out problems
AP9801368A0 (en) Benzamide treatment of mentia associated with HIV AIDS VIRUS (HIV-1) infection
Ranieri Notes On Aids In Mexico

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties